Evidence map›Paper›PMID 40619125›Full record

ArticleVirologica Sinica2025

Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.

Wen Deng, Hongxiao Hao, Ziyu Zhang, Xinxin Li, Weihua Cao, Yaqin Zhang, Shiyu Wang, Zixuan Gao, Linmei Yao, Shuojie Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Hongxiao HaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Ziyu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Xinxin LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Weihua CaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Yaqin ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Zixuan GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Linmei YaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Shuojie WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Xin WeiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China.
Wei YiDepartment of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. Electronic address: yiwei1215@163.com.
Linqing ZhaoLaboratory of Virology, Beijing Key Laboratory of Etiology of Viral Diseases in Children, Capital Institute of Pediatrics, Beijing, 100020, China. Electronic address: linqingz525@163.com.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China; Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, 100015, China. Electronic address: xieyao00120184@sina.com.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China; Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, 100015, China. Electronic address: wuhm2000@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen (HBsAg) clearance after pegylated interferon α (Peg-IFN α) treatment, a retrospective analysis was conducted on 456 patients at Beijing Ditan Hospital from 2008 to 2023 who achieved HBsAg clearance and discontinued Peg-IFN α treatment. The baseline was defined as the time of HBsAg clearance and treatment cessation. The endpoint was the first occurrence of liver adverse events (hepatocellular carcinoma or ascites) or last follow-up. Subsequently, we evaluated the incidence and risk factors of liver adverse events, along with changes in liver fibrosis, cirrhosis, and liver function indicators. During a median follow-up of 70 months, the incidence of liver adverse events was 2.30%, hepatocellular carcinoma 1.76%, and ascites 0.55%. Older age and cirrhosis were significant risk factors (HR 1.075 and 41.393, both P ​< ​0.01). The APRI score significantly improved at follow-up compared to baseline (0.53 vs. 0.25, P ​< ​0.001), and cirrhosis prevalence decreased from 5.70% to 0.88% (P ​< ​0.001). In conclusion, patients who achieved HBsAg clearance and discontinued Peg-IFN α treatment have a low risk of liver adverse events, while advanced age and cirrhosis remain major risk factors.

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsAdultAgedCarcinoma, HepatocellularFemaleFollow-Up StudiesHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedRecombinant ProteinsAntiviral AgentsHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsHBsAg lossHepatitis B virus (HBV)Hepatocellular carcinomaOutcomePegylated interferon α

Identifiers

PMID40619125
PMCPMC12414369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.